The Partnership for Research on Ebola Virus in Liberia also known as PREVAIL has released the results of the first Ebola Vaccine study that was conducted between February 2, to April 30, 2015 in Liberia.
Speaking Thursday at the Ministry of Information regular press briefing in Monrovia, Fatorma Bolay, Co-Principal Investigator for PREVAIL Vaccine study revealed that those who received the vaccine experienced temporary effects including headaches, muscle pain, fever and fatigue, which he said varied from one person to another.
He said the results show that the two tested vaccines, cAd3-EBOZ and rVSV-ZEBOV posed no major safety concerns and can produce immune responses within one month after vaccination which last for one year.
He disclosed that the results have been published on the prestigious New England Journal of Medicine.
However, Bolay stressed that they will continue monitoring the PREVAIL Study 1 participants in order to determine the long term effects or benefits.
He thanked to those who volunteered to participate in the study and help to put Liberia on the front in contributing to the world health solutions.
According to Emmanuel Boima Lansana, one of those who participated in the study, indicated that he was laughed at in his community by his own family members, including his wife who left the bed with him when he took the vaccine.
“They were all talking that I have taken Ebola and I will die but I never let it bother me because I wanted to do something that I will be remembered for in history for contributing to a healthy world,” Lansana said.
He explained that upon taking the vaccine, he experienced some muscle pain, fever and headache, which he reported and was given some pain pills that cooled the pain.